TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Influence on Erythropoetin-level by Xenon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects~* Age: \> 18 years~* legally competent to sign~* without any known medical condition or medication prescribed at the University Hospital RWTH Aachen, Germany~* Persons that are able and willing to understand and follow the instructions of the study personnel~* Signed informed consent~Exclusion Criteria:~* Smoker, alcoholic or person who regularly consumes drugs or medication~* Persons with a medical condition that is contraindicated with the planned treatment~* Known hypersensitivity against xenon~* Persons not legally competent to sign~* Simultaneous participation at any other trial~* Blood-loss due to trauma during the period of the study or 2 months previous~* Blood donation during the period of the study or 2 months previous

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 10min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 10min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 30min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 30min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 45min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 45min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 90min Xenon 15%, FiO2 75% (Type: EXPERIMENTAL): 90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
- 90min Xenon 30%, FiO2 60% (Type: EXPERIMENTAL): 90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
- 10min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 10 minutes of air medicinalis (with 75 % FiO2)
- 10min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 10 minutes of air medicinalis inhalation (with 60 % FiO2)
- 30min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 30 minutes of air medicinalis inhalation (with 75 % FiO2)
- 30min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 30 minutes of air medicinalis inhalation (with 60 % FiO2)
- 45min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 45 minutes of air medicinalis inhalation (with 75 % FiO2)
- 45min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 45 minutes of air medicinalis inhalation (with 60 % FiO2)
- 90min air medicinalis, FiO2 75% (Type: PLACEBO_COMPARATOR): 90 minutes of air medicinalis inhalation (with 75 % FiO2)
- 90min air medicinalis, FiO2 60% (Type: PLACEBO_COMPARATOR): 90 minutes of air medicinalis inhalation (with 60 % FiO2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: P3: Pacemaker Patient Profiling Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient meets Class I / Class II indications for pacing~* Patient implanted with one of the following market-approved single or dual chamber Medtronic devices: EnRhythm™, EnPulse®, Kappa® 700, Kappa® 900, Vitatron Clarity™, Vitatron Selection® AFm, Vitatron C-Series, Vitatron T-Series, or the AT500™ DDDR Pacing System~Exclusion Criteria:~* Patient is enrolled in a device or cardiovascular drug study that affects treatment and/or study device programming~* Patient whose life expectancy is less than two years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allogeneic transplant within the prior 1 year~* Age greater than or equal to 18 years~* Capable of informed consent~* Neutrophil engraftment has occurred~* This is the first clinically-recognized episode of viral respiratory tract infection after transplant~Exclusion Criteria:~* Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing pneumonia~* CMV, VZV or HSV pneumonia~* Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication (ex: BO, COP)~* Treating physician believes the risk of systemic steroids is too great~* Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent dose of another steroid~* Currently receiving pentostatin~* Mycophenolate initiated de novo or increased within the past 4 weeks~* Use of inhaled corticosteroids within the past 2 weeks for at least 1 week~* Haploidentical or T-cell depleted graft~* Lack of pre-transplant pulmonary function tests~* Evidence of a prior symptomatic viral respiratory tract infection following transplant, whether treated or not~* Allergy or adverse reaction to any of the study drugs~* Relapse or progression of the underlying malignancy~* Palliative care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
- SAMS (Type: EXPERIMENTAL): Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation for Treatment of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF \<40% using nuclear ventriculography or echocardiography within the last 6 months.~* Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.~* Patients with a 25(OH)D level between 10-25 ng/ml~Exclusion Criteria:~* Inability to give informed consent~* Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism~* Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF~* Renal dysfunction defined as serum creatinine \> 2.5 mg/dl~* Pregnant women~* Patients \<18 years of age~* Patients on vitamin D supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): A placebo loading dose will be given followed by two placebo tablets daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 6-12 at time of study enrollment.~2. Presence of chronic sinusitis: \>90 days 2 or more symptoms of purulent rhinorrhea, nasal obstruction, facial pressure/pain, or cough~3. Presence of asthma, as documented in the medical record by the patient's pediatrician and/or pulmonologist~4. Failure of medical management of pediatric chronic rhinosinusitis, which current guidelines recommend extended empiric antibiotics for 21 days, which will be either Augmentin or clindamycin in penicillin allergic patients, at standard pediatric weight based dosing. In addition, Flonase nasal spray and nasal saline treatment for three weeks. Failure is considered persistent symptoms despite treatment with the above within the past year.~Exclusion Criteria:~1. Previous sinus surgery,~2. Previous adenoidectomy, or~3. Presence of cystic fibrosis,~4. Presence of antrochoanal polyp,~5. Immunodeficiency~6. Fungal infection.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Adenoidectomy (Type: ACTIVE_COMPARATOR): Current standard of care for pediatric chronic rhino sinusitis.
- Adenoidectomy plus Endoscopic Sinus Surgery (Type: EXPERIMENTAL): endoscopic sinus surgery in addition to adenoidectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven squamous cell carcinoma of the oral cavity.~* Primary tumor sites eligible: oral cavity. Although they are admittedly of squamous cell types, the following tumors will be excluded because their responsiveness to chemotherapy may differ: tumors of the nasal and paranasal cavities and of the nasopharynx. Oral cavity tumors with mandible invasion are excluded because the tumor biology and management of these tumors is more complex and will likely include upfront surgical resection.~* Stage 3 or 4 disease without evidence of distant metastases verified by chest x-ray, abdominal ultrasound, or CT scan (liver function test abnormalities); bone scan in case of local symptoms.~* At least one uni- or bi-dimensionally measurable lesion.~* Age ≥ 18 years.~* World Health Organization (WHO) performance status of 2 or less.~* No active alcohol addiction.~* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.~Exclusion Criteria:~* Pregnant or breast feeding~* Previous malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal, or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years.~* Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.~* Patients who experience an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry.~* Concurrent treatment with any other anti-cancer therapy.~* Participation in an investigational trial within 30 days of study entry.~* Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.~* No previous chemotherapy or radiotherapy for any reason and no previous surgery for SCCHN \[squamous cell carcinoma of the head and neck\] (other than biopsy) are allowed at the time of study entry.~* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recipients of Docetaxel, Cisplatin, 5-Fluorouracil (Type: EXPERIMENTAL): Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Contrast Flow Patterns of TESI Using the Inferior-Anterior Position as the Final Needle Tip Position.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* History of lumbosacral radiculopathy or lumbar herniated nucleus pulposus~* Scheduled for TFESI at GW Spine and Pain Center~Exclusion Criteria:~* Pregnant or plan on becoming pregnant~* Have undergone TFESI in the past year~* Opioid habituation~* Lumbo-sacral stenosis~* Lumbar surgery~* Lumbar spondylolisthesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transforaminal Epidural Steroid Injection (Type: None): Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is available~* Participants may be enrolled to either or both the clinical or genomic portions of the study~* The minimum data required to be able to include a subject for analysis of clinical prognostic factors are:~  * HIV status, and for HIV subjects include cluster of differentiation (CD)4 count, HIV viral load closest to time of diagnosis~ * Age at PEL diagnosis~ * Gender~ * Stage at diagnosis~ * Treatment of PEL~ * Response to treatment~ * Survival status at 2 years~ * Pathology slides (or paraffin block) for central review~* The minimum data required to be able to include a subject for analysis of genomic prognostic factors are:~  * Availability of a pathologic specimen of PEL that will be submitted for genomic analysis~ * Survival status at 2 years~Exclusion Criteria:~* Patients who do not fulfill the criteria as listed above are ineligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chart review, RNA sequencing, microarray (Type: None): Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Foveal center-involving macular edema secondary to BRVO diagnosed within 12 months before study enrollment~2. ETDRS chart BCVA: 63 to 77 letters (20/32 to 20/50 Snellen equivalent)~3. CFT \>= 300 um (mean of measurements obtained at screening and Day 0)~4. Signed consent informed~5. male or female, age ≥18 years old~Exclusion Criteria:~1. Prior episode of RVO: Past history of RVO in the study eye diagnosed before 1 year of study enrollment.~2. BCVA improvement \>10 letters between screening and Day 0~3. History of other ocular diseases (e.g. diabetic retinopathy, age-related macular degeneration)~4. Laser treatment within 3 months before baseline~5. Intraocular corticosteroid use within 3 months before baseline~6. Anti-vascular endothelial growth factor (VEGF) treatment in the study or fellow eye within 3 months before baseline~7. Intraocular surgery other than cataract surgery, Cataract surgery within 6 months before baseline~8. Stroke or myocardial infarction ≤3 months before baseline~9. Pregnancy or plan to have baby in female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab group (Type: EXPERIMENTAL): Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
- Standard of care group (Type: SHAM_COMPARATOR): Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* ≥ 6th grade English literacy~* agree to use personal or study-provided smartphone/applications~* agree to complete phone-based or in-person surveys throughout 26 week study~* expired CO \> 6 ppm at baseline visit (suggesting current smoker)~* currently smoke ≥ 5 cigarettes per day~* willing to make quit attempt 7 days after baseline visit~Exclusion Criteria:~* \< 18 years of age~* history of seizures or allergic reaction to varenicline~* report current suicidality~* taking anti-depressants or anti-psychotic medications~* pregnant or planning to become pregnant~* currently breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline/Counseling + Med Reminders (VAR+REM) (Type: EXPERIMENTAL): Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
- Varenicline/Counseling (VAR+NREM) (Type: EXPERIMENTAL): Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
- Varenicline/Counseling + Oral NRT (VAR+NRT+NREM) (Type: EXPERIMENTAL): Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
- Varenicline/Counseling + Oral NRT + Med Reminders (VAR+NRT+REM) (Type: EXPERIMENTAL): Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years old and skeletally mature~* KOOS Pain subscale score is less than 65 (i.e. moderate pain)~* KOOS Activities of Daily Living score is less than 70 (i.e. moderate functional limitations)~* ICRS grade 3 or 4 cartilage lesion on the medial femoral condyle, lateral femoral condyle or trochlea measuring less than or equal to 15mm in diameter~* Stable meniscus with greater than 50% remaining bilaterally~* Mental capacity and willingness to comply with the post-operative rehabilitation plan and follow-up evaluations~* Written informed consent~Exclusion Criteria:~* Body mass index greater than 35~* Contraindication for MRI~* Previous microfracture, autograft implantation, allograft implantation or autologous chondrocyte implantation procedure on the damaged cartilage surface~* Knee ligament surgery within the past 6 months~* Clinically significant knee malalignment~* Osteoarthritis in the knee~* Multiple cartilage lesions~* Inflammatory arthropathy (i.e. rheumatoid arthritis, systemic lupus or active gout)~* Active infection in either lower limb~* Hyaluronic acid or cortisone injections within the past 3 months~* History of substance abuse~* Current participation in a study of an investigational product for a similar purpose~* Active litigation for the knee injury

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
- Control (Type: ACTIVE_COMPARATOR): Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues